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multiple or centrally localized lesions, a wish for pregnancy), 
the treatment policy was highly variable. Pregnancy was not 
discouraged in 15 hospitals, but in 11 (65%) of these, strictly 
defined conditions were noted: frequent follow-up, periph-
eral tumour localization that makes surgery easier if neces-
sary, stable tumour size, and a good informed consent.  Con-
clusion: The management of HAs in the Netherlands is rath-
er uniform, except in complex cases in which multiple factors 
may influence policy.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 The diagnosis of hepatocellular adenoma (HA) has a 
great impact on the lives of young women. HA is a benign 
tumour that usually presents as a solitary nodule; in a 
minority, multiple lesions are seen. This tumour is most-
ly detected in females within their reproductive years, as-
sociated with a long-term use of oral contraceptives (OC). 
The incidence is low, estimated to be 3–4/100,000 in long-
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 Abstract 
 Background: The diagnosis of hepatocellular adenoma (HA) 
has a great impact on the lives of young women and may 
pose clinical dilemmas to the clinician since there are no 
standardized protocols to follow. We aimed to establish ex-
pert opinions on diagnosis and treatment of HA by collect-
ing data from a nationwide questionnaire in the Nether-
lands.  Methods: A questionnaire was sent to 20 Dutch hos-
pitals known to offer hepatologic and surgical experience on 
liver tumours.  Results: 17 hospitals (85%) responded to the 
questionnaire. Annually, a median of 52 patients presented 
with a solid liver tumour. In 15 (88%) hospitals, hepatic ade-
nomas were diagnosed with contrast-enhanced, multiphase 
spiral CT or MRI. In 2 (12%) hospitals, histology was required 
as part of a management protocol. Surveillance after with-
drawal of oral contraceptives was the initial policy in all clin-
ics. MRI, CT or ultrasound was used for follow-up. Criteria for 
surgical resection were a tumour size  1 5 cm and abdominal 
complaints. In 5 (29%) hospitals, patients were dismissed 
from follow-up after surgery. In complex cases (e.g. large, 
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term OC users  [1] . During pregnancy the presence of HA 
can be complicated by growth and rupture which is in-
duced by elevated hormone levels. Rupture and bleeding 
is associated with high maternal and fetal mortality  [2–5] . 
Malignant transformation of HA to hepatocellular carci-
noma (HCC) occurs rarely, but the true incidence of ma-
lignancy arising within HA is not known  [6, 7] . Patients 
with HA may present with right upper quadrant abdom-
inal pain secondary to bleeding, elevated liver enzymes 
and symptoms of life-threatening haemorrhage. Howev-
er, most patients are asymptomatic. Since the introduc-
tion and widespread use of highly advanced imaging mo-
dalities, the number of solitary nodules that are found by 
accident has greatly increased in the last decennium  [8] .
 The debate whether to manage solitary adenomas by 
surveillance or surgical resection continues. Conservative 
management of HA frequently implies cessation of the use 
of OC, intermittent follow-up by radiological imaging and 
negative advice regarding pregnancy. Surgical treatment 
of HA is associated with a risk of morbidity and mortality 
and does not guarantee relief of complaints. The most im-
portant reason for surgery is size of the lesion, since rup-
ture as well as malignant transformation is seldom report-
ed in lesions  ! 5 cm  [7] . Patients with an adenoma which 
is  ! 5 cm and who do have a wish for pregnancy might also 
benefit from an early intervention in order to avoid an in-
vasive treatment during pregnancy  [9] . In practice, man-
agement strategy is not only determined by the size of the 
HA, but may also depend on complaints, the number and 
localization of nodules, a wish for pregnancy and surgical 
risks. Therefore, the policy for HA should be standardized 
while there is a place for a custom-made approach when 
considering these factors.
 For this purpose, we collected data by a nationwide 
questionnaire in order to establish the most common ap-
proach in diagnosis and treatment of HA in the Nether-
lands.
 Methods 
In January 2005, a questionnaire was sent to 20 Dutch univer-
sity centres and hospitals with a large programme of hepatobiliary 
surgery ( table  1 ). Hepatobiliary surgeons in these hospitals all 
participate in the Dutch Liver Surgery Working Group of which 
is a division of the Dutch Society for Surgery. Both the depart-
ments of surgery and gastrointestinal diseases were invited to take 
part in this questionnaire. In May 2005, a reminder was sent to 
those who had not responded. The questionnaire included multi-
ple-choice questions concerning incidence, diagnosis, treatment 
and follow-up of HA in the Netherlands. There was a possibility 
to add a comment next to each question. Specialists were asked 
what they would advise a women with a HA and a wish for preg-
nancy. In questions concerning treatment, we proposed that a 
conservative policy was followed initially. Thereafter, the ques-
tion was asked on what criteria invasive treatment could have 
been chosen. Clinical dilemmas on HA were discussed on the ba-
sis of 5 imaginary cases. These cases had an open-answer option. 
Statistical data were analyzed using SPSS for Windows Version 
13.0 (SPSS, Chicago, Ill., USA).
 Results 
 Of the 20 hospitals (8 university centres and 9 general 
hospitals), 17 (85%) responded. In 8 (47%) of these 17 hos-
pitals, data on incidence were from prospective databas-
es. Data from the remaining hospitals were based on ret-
rospective analyses or estimates by specialists.
 Incidence 
 A median of 52 patients with a solid liver tumour pre-
sented annually per hospital (range 3–415). Between 1 
Table 1.  Summary of questionnaire concerning policy in case of 
HA held in the Netherlands
Incidence
Are patients with solid liver tumours registered?
How many liver tumours are seen each year?
How many of them are benign?
Is there a multidisciplinary consultation team to determine
treatment policy?
Diagnosis
Which imaging tools are being used for diagnosis?
Is there a role for liver biopsy in diagnosis of hepatocellular
adenoma?
Are patients being tested for hepatitis B or C infection?
Therapy
Define surveillance
What are criteria to switch to invasive therapy?
What would be the first option?
Does the histological diagnosis of the resected specimen always
confirm preoperative histological diagnosis?
Follow-up
Is there a follow-up after conservative management?
Is there a follow-up after surgery?
What kind of follow-up is being used and for how long?
What are the reasons for follow-up?
Pregnancy
What do you advise a patient with a wish for pregnancy?
Did you ever have a pregnant patient with an adenoma in situ?
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and 40% of these patients had benign lesions with a dif-
ferential diagnosis of adenoma, focal nodular hyperpla-
sia, and haemangioma.
 Diagnostics 
 In 16 (94%) hospitals the policy for individual patients 
was determined by a multidisciplinary consultation of a 
surgeon, hepatologist, radiologist, oncologist and pathol-
ogist. The diagnosis of HA was usually based on imaging 
modalities. Multiphase spiral CT series were performed 
in 12 (71%) hospitals. Multiphase contrast-enhanced 
MRI series were also applied in 12 hospitals. These data 
show that in 15 (88%) hospitals HAs were diagnosed with 
contrast-enhanced, multiphase spiral CT or MRI series. 
In 2 (12%) hospitals a liver biopsy was required for histo-
logical diagnosis. 13 (76%) hospitals followed the stan-
dard policy to test patients with a solid nodule for hepa-
titis B and C. Additional tests included serum analyses 
for iron overload (8 (53%) hospitals),   1 -antitrypsin defi-
ciency and alcohol consumption (both in 2 (12%) hospi-
tals).
 Treatment 
 In 12 (71%) hospitals the policy for HA was not struc-
tured in a protocol. Surveillance was the initial strategy 
in all hospitals. This policy consisted of withdrawal of OC 
and outpatient control by an imaging modality at least 
once. The kind of imaging tool that was used varied; 
MRI, CT or ultrasound was performed for follow-up in 
respectively 7 (41%), 10 (59%) and 8 (47%) hospitals. The 
interval between follow-up episodes also varied. Follow-
up after 6 months was mentioned in 10 (59%) hospitals, 
but intervals of 3, 4, or 12 months were also reported. An-
other question concerned the situation in which a patient 
could resume the use of OC. This was assumed to be pos-
sible in 8 (47%) hospitals. Six hospitals reported that in 
patients who did not show a regression of the lesion up to 
1 year after stopping, the use of OC could be resumed. 
Comments were made that patients tended not to resume 
the use of OC and often wanted to have imaging informa-
tion about renewed growth.
 Major criteria for surgical resection were a tumour size 
 1 5 cm (16 (94%) hospitals) and abdominal complaints (15 
clinics, 88%). In those cases the decision for radical resec-
tion of the liver tumour was unanimous. In case of mul-
tiple adenomas the motivation for surgical intervention 
was determined by the pattern of complaints, size and 
localization of the lesions, opportunities to treat all tu-
mours and the availability and use of alternative treat-
ments such as radiofrequency ablation.
 Other criteria were a wish for pregnancy, signs of ma-
lignancy, tumour growth, diagnostic doubt and localiza-
tion in respectively 7 (41%), 10 (59%), 4 (24%), 5 (29%) and 
7 (41%) of all hospitals.
 In 14 (82%) hospitals it had occurred that histological 
analysis of the resected specimen showed another diag-
nosis compared to the preoperative diagnosis. Most of 
these cases were focal nodular hyperplasia. Five (29%) 
hospitals mentioned a few cases in which a HCC was di-
agnosed after resection.
 Follow-Up 
 Patients who were managed by surveillance were fol-
lowed for a median period of 4 years (range 1–10) in all 
hospitals. In 14 (82%) of the 17 hospitals, radiological 
tools were used to monitor growth and malignant trans-
formation. After surgical resection, in 5 (29%) hospitals 
follow-up was not considered necessary. In the other cas-
es, patients were followed for a median period of 2 years 
(range 1–5). Growth or residual lesions were monitored. 
Pregnancy was not discouraged in 15 hospitals, but in 11 
(65%) of these, strictly defined conditions such as fre-
quent follow-up (4 hospitals), a peripheral tumour local-
ization that makes surgery easier if necessary (2 hospi-
tals), a stable tumour size (2 hospitals), and a good in-
formed consent about the risks in case of pregnancy (2 
hospitals) were noted. No restrictions in patients with HA 
were imposed in 4 hospitals. In only 1 hospital, 1 patient 
was advised to postpone pregnancy until a surgical resec-
tion had been performed. Seven hospitals reported 1 or 
more patient(s) who presented with an adenoma during 
pregnancy; growth of the tumour occurred in 4 cases. 
Three of them fulfilled their pregnancy without compli-
cations. In 1 hospital, 1 patient underwent a surgical re-
section during the first trimester of pregnancy and an-
other patient underwent a premature caesarean section 
in the third trimester because of a rapidly growing ade-
noma.
 Imaginary Cases 
 Clinical dilemmas on HA were investigated on the 
basis of 5 imaginary cases ( table 2 ). Small asymptomatic 
adenomas were managed by surveillance. In case of a 
large adenoma which was located centrally in the liver, 
the choice between surveillance and surgical resection 
was difficult to make and answers varied widely on this 
point. In 6 hospitals an additional biopsy was preferred 
in case of multiple adenomas in order to exclude malig-
nancy.
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 Discussion 
 Data obtained from this survey show that most Dutch 
specialists who responded to the questionnaire rely on 
multiphase contrast-enhanced CT or MRI series to con-
firm the diagnosis of HA. Using these techniques it is 
usually possible to differentiate adenomas from other be-
nign lesions such as focal nodular hyperplasia and hae-
mangioma as well as from malignancies  [10–12] . No strict 
consensus for the optimal imaging work-up of liver le-
sions was found. Most often, MRI was applied to charac-
terize liver lesions by using multiphase dynamic contrast-
enhanced techniques. The availability of tissue-specific 
contrast media in MRI, e.g. gadobenate dimeglumine, 
which is one of the most recently used agents in hepatic 
imaging, permits lesion characterisation based on its cel-
lular composition, enhancement pattern and morpholog-
ical features  [13] . The use of this highly advanced imaging 
modality during differential diagnosis of a focal liver le-
sion will prevent unnecessary liver biopsy or surgery. The 
role of ultrasound-guided percutaneous liver biopsy is 
debatable as various studies indicate that histology on 
needle biopsies may not be conclusive regarding HA, fo-
cal nodular hyperplasia and well-differentiated HCC  [14–
16] . Only 2 hospitals in our questionnaire indicated that 
a biopsy was required to establish the diagnosis of HA.
 Conservative management, including imaging sur-
veillance and discontinuation of OC, was the initial pol-
icy in all hospitals ( fig. 1 ). This strategy is in accordance 
with several studies advocating a conservative approach 
 [14, 15, 17, 18] . Some authors emphasize the possibility of 
malignant transformation in large lesions  [17, 19, 20] and 
tend to resect HAs  1 5 cm. The relationship between tu-
mour size and bleeding risk is unclear. After rupture or 
bleeding of HAs it is difficult to identify the size of the 
original tumour as a haematoma may disturb imaging 
reliability. While most patients with an adenoma are
asymptomatic, up to 60% of those who present with 
symptoms do have signs of bleeding  [15, 19, 21] . Al-
though tumour size is the most important factor to de-
cide whether to manage by observation or to perform a 
surgical resection, abdominal pain was an equally impor-
tant determinant. Surgical resection of HA is described 
as an effective method to reduce complaints. However, 
various experts stress that it should be ascertained that 
symptoms are related to the HA  [15] . Abdominal pain 
Table 2. I maginary cases and answers of specialists from 17 hospitals with expertise in hepatobiliary surgery
Case Policy Hospitals, n
48-year-old female with a hilar-located adenoma of 8 cm 
and signs of intrahepatic bleeding
Resection if possible
Arterial embolisation
RFA
Observation
 7 (41%)
 4 (24%)
 1 (6%)
 5 (29%)
23-year-old female with an incidentally found adenoma
located in the middle of the right lobe; she uses OC and
has a clear wish for pregnancy in future
Surveillance
Surveillance, invasive treatment in case of growth
or no regression
RFA
11 (65%)
 4 (24%)
 2 (12%)
40-year-old obese female diagnosed with
4 lesions suspected for adenoma: 2 are
located in the right liver (diameter 6 and 2 cm)
and 2 in the left (diameter 2 and 3 cm)
Surveillance
Resection of largest one
Resection of largest adenoma and RFA of other lesions
RFA of largest lesion
 7 (41%)
 4 (24%)
 5 (29%)
 1 (6%)
Female patient with an adenoma of 8 cm; regression
occurred after stopping OC; the tumour now measures
4 cm and she wants to become pregnant
Resection before pregnancy
RFA before pregnancy
Good informed consent and surveillance during pregnancy
10 (59%)
 2 (12%)
 5 (29%)
Female patient with an adenoma of 4 cm, which did not 
show regression after stopping OC; she wants to become 
pregnant
Frequent surveillance during pregnancy
Resection or RFA before pregnancy
Informed consent, the patient has to decide for surveillance,
surgery or RFA
 8 (47%)
 7 (41%)
 2 (12%)
R FA = Radiofrequency ablation; OC = oral contraceptives.
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often arises due to the sudden increase in volume of a 
haematoma. Bleeding can be managed conservatively 
and resorption of a haematoma can equally reduce symp-
toms. Many experts answered to favour a wait-and-see 
policy in dynamically stable patients  [22] . The localiza-
tion of a HA and the surgical risks determine whether a 
surgical approach is feasible. If there are doubts about ra-
diological diagnosis, specialists are more likely to favour 
surgical resection, i.e. to exclude HCC.
 Clinical dilemmas occur when multiple factors men-
tioned above are to be considered. In these situations it is 
complex to define an appropriate treatment strategy and 
comments varied considerably between specialists. The 
use of imaging modalities is essential during follow-up of 
HA, since there is a large discrepancy between clinical 
signs of patients and the size or growth of the adenoma.
 It has to be noted that it is a difficult decision to dis-
courage pregnancy in otherwise healthy young women. 
Pregnancy was not discouraged in most of the clinics, but 
in most of the imaginary cases, a majority of experts 
wanted to exclude the risk of bleeding by resection before 
pregnancy. In a recently published review of 27 women 
who were pregnant with a HA in situ, rupture occurred 
in 16 of them, leading to death of mother or child in 7 
cases  [5] . However, it has to be noted that all of these case 
reports were published in the 1970s or 1980s. In this pe-
riod, the routine use of ultrasonography was less frequent 
and there might have been a delay in diagnosis because of 
confusion with other pregnancy-related diseases like pre-
eclampsia or pulmonary embolism. When women are in-
formed about the potential risks, it is safe to allow preg-
nancy, especially if the lesion is accessible for limited sur-
gical resection. It seems unjustified to discourage all 
women with HAs from pregnancy.
 In women with a clear diagnosis of a single HA with a 
diameter  ! 5 cm and without complaints, most experts 
advise a conservative policy. After discontinuation of 
OC, HA does not seem to grow and the likelihood of 
bleeding decreases  [23] . If the diagnosis of HA is uncer-
tain and the diagnosis HCC remains in differential diag-
nosis, radical resection of the tumour is recommended. 
At our centre, surgical treatment of solitary adenomas is 
restricted to patients having lesions that measure  6 5 cm, 
in those patients in which malignancy cannot be exclud-
ed and to lesions that do not show adequate regression 
after discontinuation of OC, especially in case of women 
a b c
d e f
 Fig. 1. Contrast-enhanced multiphase MRI series of a patient with HA:  a T 2 -weighted,  b arterial phase,  c delayed 
phase during use of OC,  d T 2 -weighted,  e arterial phase, and  f delayed phase after stopping use of oral contra-
ceptives. 
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with a wish for pregnancy  [9, 15] . However, due to the in-
vasive nature of hepatic surgery and the risk of postop-
erative morbidity, other treatment strategies are needed. 
Several authors have described the successful application 
of minimal invasive strategies such as transarterial 
(chemo)embolisation and radiofrequency ablation  [24–
28] . The role of these alternative treatments in case of HA 
still needs to be established in clinical studies.
 Recent identification of gene mutations, such as muta-
tions in hepatocyte nuclear factor 1  and   -catenin that 
seem to be correlated to the phenotype of HA, will create 
a basis for a new genotype/phenotype classification of 
HAs. These developments will hopefully permit signifi-
cant improvements in liver biopsy interpretation, creat-
ing the possibility to predict the risk of bleeding and ma-
lignant transformation and the ability to propose better 
guidelines in terms of surveillance and treatment  [29, 30] .
 We conclude that the management of HAs in the 
Netherlands is rather uniform. However, in complex situ-
ations where multiple factors may play a role in determin-
ing the management strategy, such as pregnancy or mul-
tiple adenomas, respondents’ opinions are very variable 
regarding treatment and follow-up.
 Because evidence-based data are scarce in the litera-
ture, it is recommended that Dutch specialists exchange 
knowledge and data of patients with HA to develop the 
most adequate guidelines in complex situations, justify-
ing a custom-made approach. This will prevent unneces-
sary surgery and may offer well-balanced advice on preg-
nancy in case of more complex cases.
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